Orf virus interferes with MHC class I surface expression by targeting vesicular transport and Golgi

BMC Veterinary Research

Hanns-Joachim Rziha¹  Michael R Knittler¹  Frederic Emschermann¹  Jörg Rohde¹ 

[1] Friedrich-Loeffler-Institute, Federal Research Institute of Animal Health, Institute of Immunology, Greifswald-Insel Riems, Germany

关键词: Golgi apparatus;    Immunomodulation;    Subversion;    MHC class I;    Parapoxvirus;    Orf virus;   

Others  :  1119773
DOI  :  10.1186/1746-6148-8-114

 received in 2012-03-07, accepted in 2012-05-29,  发布年份 2012

【 摘 要 】

Background

The Orf virus (ORFV), a zoonotic Parapoxvirus, causes pustular skin lesions in small ruminants (goat and sheep). Intriguingly, ORFV can repeatedly infect its host, despite the induction of a specific immunity. These immune modulating and immune evading properties are still unexplained.

Results

Here, we describe that ORFV infection of permissive cells impairs the intracellular transport of MHC class I molecules (MHC I) as a result of structural disruption and fragmentation of the Golgi apparatus. Depending on the duration of infection, we observed a pronounced co-localization of MHC I and COP-I vesicular structures as well as a reduction of MHC I surface expression of up to 50%. These subversion processes are associated with early ORFV gene expression and are accompanied by disturbed carbohydrate trimming of post-ER MHC I. The MHC I population remaining on the cell surface shows an extended half-life, an effect that might be partially controlled also by late ORFV genes.

Conclusions

The presented data demonstrate that ORFV down-regulates MHC I surface expression in infected cells by targeting the late vesicular export machinery and the structure and function of the Golgi apparatus, which might aid to escape cellular immune recognition.

【 授权许可】

   
2012 Rohde et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Büttner M, Rziha HJ: Parapoxviruses: from the lesion to the viral genome. J Vet Med B Infect Dis Vet Public Health 2002, 49(1):7-16.
• [2]Haig DM: Orf virus infection and host immunity. Curr Opin Infect Dis 2006, 19(2):127-131.
• [3]Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron C, Sypula J, Nazarian SH, Lucas A, McFadden G: Poxviruses and immune evasion. Annu Rev Immunol 2003, 21:377-423.
• [4]Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA: A homolog of interleukin-10 is encoded by the poxvirus orf virus. J Virol 1997, 71(6):4857-4861.
• [5]McInnes CJ, Wood AR, Mercer AA: Orf virus encodes a homolog of the vaccinia virus interferon-resistance gene E3L. Virus Genes 1998, 17(2):107-115.
• [6]Deane D, McInnes CJ, Percival A, Wood A, Thomson J, Lear A, Gilray J, Fleming S, Mercer A, Haig D: Orf virus encodes a novel secreted protein inhibitor of granulocyte-macrophage colony-stimulating factor and interleukin-2. J Virol 2000, 74(3):1313-1320.
• [7]Imlach W, McCaughan CA, Mercer AA, Haig D, Fleming SB: Orf virus-encoded interleukin-10 stimulates the proliferation of murine mast cells and inhibits cytokine synthesis in murine peritoneal macrophages. J Gen Virol 2002, 83(Pt 5):1049-1058.
• [8]Lateef Z, Baird MA, Wise LM, Young S, Mercer AA, Fleming SB: The chemokine-binding protein encoded by the poxvirus orf virus inhibits recruitment of dendritic cells to sites of skin inflammation and migration to peripheral lymph nodes. Cell Microbiol 2010, 12(5):665-676.
• [9]Abendroth A, Arvin A: Immune evasion mechanisms of varicella-zoster virus. Arch Virol Suppl 2001, 17:99-107.
• [10]Williams DB, Vassilakos A, Suh WK: Peptide presentation by MHC class I molecules. Trends Cell Biol 1996, 6(7):267-273.
• [11]Ambagala AP, Solheim JC, Srikumaran S: Viral interference with MHC class I antigen presentation pathway: the battle continues. Vet Immunol Immunopathol 2005, 107(1–2):1-15.
• [12]Hewitt EW: The MHC class I antigen presentation pathway: strategies for viral immune evasion. Immunology 2003, 110(2):163-169.
• [13]Heemels MT, Ploegh H: Generation, translocation, and presentation of MHC class I-restricted peptides. Annu Rev Biochem 1995, 64:463-491.
• [14]Jonjic S, Babic M, Polic B, Krmpotic A: Immune evasion of natural killer cells by viruses. Curr Opin Immunol 2008, 20(1):30-38.
• [15]Zuniga MC, Wang H, Barry M, McFadden G: Endosomal/lysosomal retention and degradation of major histocompatibility complex class I molecules is induced by myxoma virus. Virology 1999, 261(2):180-192.
• [16]Byun M, Wang X, Pak M, Hansen TH, Yokoyama WM: Cowpox virus exploits the endoplasmic reticulum retention pathway to inhibit MHC class I transport to the cell surface. Cell Host Microbe 2007, 2(5):306-315.
• [17]Dasgupta A, Hammarlund E, Slifka MK, Fruh K: Cowpox virus evades CTL recognition and inhibits the intracellular transport of MHC class I molecules. J Immunol 2007, 178(3):1654-1661.
• [18]Byun M, Verweij MC, Pickup DJ, Wiertz EJ, Hansen TH, Yokoyama WM: Two mechanistically distinct immune evasion proteins of cowpox virus combine to avoid antiviral CD8 T cells. Cell Host Microbe 2009, 6(5):422-432.
• [19]Alzhanova D, Edwards DM, Hammarlund E, Scholz IG, Horst D, Wagner MJ, Upton C, Wiertz EJ, Slifka MK, Fruh K: Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition. Cell Host Microbe 2009, 6(5):433-445.
• [20]Traub LM, Bannykh SI, Rodel JE, Aridor M, Balch WE, Kornfeld S: AP-2-containing clathrin coats assemble on mature lysosomes. J Cell Biol 1996, 135(6 Pt 2):1801-1814.
• [21]Rabouille C, Klumperman J: Opinion: The maturing role of COPI vesicles in intra-Golgi transport. Nat Rev Mol Cell Biol 2005, 6(10):812-817.
• [22]Lowe M, Kreis TE: In vivo assembly of coatomer, the COP-I coat precursor. J Biol Chem 1996, 271(48):30725-30730.
• [23]Abendroth A, Lin I, Slobedman B, Ploegh H, Arvin AM: Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol 2001, 75(10):4878-4888.
• [24]Campadelli G, Brandimarti R, Di Lazzaro C, Ward PL, Roizman B, Torrisi MR: Fragmentation and dispersal of Golgi proteins and redistribution of glycoproteins and glycolipids processed through the Golgi apparatus after infection with herpes simplex virus 1. Proc Natl Acad Sci U S A 1993, 90(7):2798-2802.
• [25]Quiner CA, Jackson WT: Fragmentation of the Golgi apparatus provides replication membranes for human rhinovirus 1A. Virology 2010, 407(2):185-195.
• [26]Sandoval IV, Carrasco L: Poliovirus infection and expression of the poliovirus protein 2B provoke the disassembly of the Golgi complex, the organelle target for the antipoliovirus drug Ro-090179. J Virol 1997, 71(6):4679-4693.
• [27]Beske O, Reichelt M, Taylor MP, Kirkegaard K, Andino R: Poliovirus infection blocks ERGIC-to-Golgi trafficking and induces microtubule-dependent disruption of the Golgi complex. J Cell Sci 2007, 120(Pt 18):3207-3218.
• [28]Schmelz M, Sodeik B, Ericsson M, Wolffe EJ, Shida H, Hiller G, Griffiths G: Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J Virol 1994, 68(1):130-147.
• [29]Tan JL, Ueda N, Mercer AA, Fleming SB: Investigation of orf virus structure and morphogenesis using recombinants expressing FLAG-tagged envelope structural proteins: evidence for wrapped virus particles and egress from infected cells. J Gen Virol 2009, 90(Pt 3):614-625.
• [30]Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM, Campo MS: E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 2005, 113(2):276-283.
• [31]Girod A, Storrie B, Simpson JC, Johannes L, Goud B, Roberts LM, Lord JM, Nilsson T, Pepperkok R: Evidence for a COP-I-independent transport route from the Golgi complex to the endoplasmic reticulum. Nat Cell Biol 1999, 1(7):423-430.
• [32]Kirchhausen T: Three ways to make a vesicle. Nat Rev Mol Cell Biol 2000, 1(3):187-198.
• [33]Pierini R, Cottam E, Roberts R, Wileman T: Modulation of membrane traffic between endoplasmic reticulum, ERGIC and Golgi to generate compartments for the replication of bacteria and viruses. Semin Cell Dev Biol 2009, 20(7):828-833.
• [34]Zhang L, Lee SY, Beznoussenko GV, Peters PJ, Yang JS, Gilbert HY, Brass AL, Elledge SJ, Isaacs SN, Moss B, et al.: A role for the host coatomer and KDEL receptor in early vaccinia biogenesis. Proc Natl Acad Sci U S A 2009, 106(1):163-168.
• [35]Yilla M, Tan A, Ito K, Miwa K, Ploegh HL: Involvement of the vacuolar H(+)-ATPases in the secretory pathway of HepG2 cells. J Biol Chem 1993, 268(25):19092-19100.
• [36]Fischer T, Planz O, Stitz L, Rziha HJ: Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge infection in mice. J Virol 2003, 77(17):9312-9323.
• [37]Brodsky FM, Parham P: Evolution of HLA antigenic determinants: species cross-reactions of monoclonal antibodies. Immunogenetics 1982, 15(2):151-166.
• [38]Housawi FM, Roberts GM, Gilray JA, Pow I, Reid HW, Nettleton PF, Sumption KJ, Hibma MH, Mercer AA: The reactivity of monoclonal antibodies against orf virus with other parapoxviruses and the identification of a 39 kDa immunodominant protein. Arch Virol 1998, 143(12):2289-2303.
• [39]Fischer T, Büttner M, Rziha HJ: T helper 1-type cytokine transcription in peripheral blood mononuclear cells of pseudorabies virus (Suid herpesvirus 1)-primed swine indicates efficient immunization. Immunology 2000, 101(3):378-387.
• [40]Ashrafi GH, Tsirimonaki E, Marchetti B, O'Brien PM, Sibbet GJ, Andrew L, Campo MS: Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins. Oncogene 2002, 21(2):248-259.
• [41]Henkel M, Planz O, Fischer T, Stitz L, Rziha HJ: Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant. J Virol 2005, 79(1):314-325.